Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Melanoma treatment is being revolutionized by the development of effective immunotherapeutic approaches. These strategies include blockade of immune-inhibitory receptors on activated T cells; for example, using monoclonal antibodies against CTLA-4, PD-1, and PD-L1 (refs 3-5). However, only a subset of patients responds to these treatments, and data suggest that therapeutic benefit is preferentially achieved in patients with a pre-existing T-cell response against their tumour, as evidenced by a baseline CD8(+) T-cell infiltration within the tumour microenvironment. Understanding the molecular mechanisms that underlie the presence or absence of a spontaneous anti-tumour T-cell response in subsets of cases, therefore, should enable the development of therapeutic solutions for patients lacking a T-cell infiltrate. Here we identify a melanoma-cell-intrinsic oncogenic pathway that contributes to a lack of T-cell infiltration in melanoma. Molecular analysis of human metastatic melanoma samples revealed a correlation between activation of the WNT/β-catenin signalling pathway and absence of a T-cell gene expression signature. Using autochthonous mouse melanoma models we identified the mechanism by which tumour-intrinsic active β-catenin signalling results in T-cell exclusion and resistance to anti-PD-L1/anti-CTLA-4 monoclonal antibody therapy. Specific oncogenic signals, therefore, can mediate cancer immune evasion and resistance to immunotherapies, pointing to new candidate targets for immune potentiation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Tumor-intrinsic activation of the Wnt/β-catenin pathway (15) and deletion or mutation of Pten (16) have been shown to lead to deficient T cell infiltration into the tumor microenvironment and resistance to checkpoint blockade immunotherapy.”
From The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients (2018) · cites this paper as [15]
In the citing paper
“We reveal that the APOE variants exert cell-intrinsic effects on melanoma that impact primary tumor growth and metastatic capacity in a BrafV600E-driven GEMM, a model that has provided numerous important insights into melanoma biology (12,38–40).”
From Apolipoprotein E2 Stimulates Protein Synthesis and Promotes Melanoma Progression and Metastasis (2023) · cites this paper as [12]
In the citing paper
“Combinatorial biomarker strategies that capture attributes of the host and tumor-immune ecosystem will be essential (Fig. 2; refs.121-124).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [123]
In the citing paper
“For example, tumor cell-intrinsic WNT/β-catenin activation has been shown to lead to exclusion of T cells within the TME (123, 155, 156).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [123]
In the citing paper
“Mechanistic studies revealed that Wnt-induced decrease in the expression of the chemokine CCL4 hindered the recruitment of CD103+ DCs and T cells to the tumor microenvironment (Spranger et al., 2015).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Spranger et al., 2015
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Analyzing real-time PCR data by the comparative CT method
Schmittgen, T. D., & Livak, K. J. (2008) · Nature Protocols · doi:10.1038/nprot.2008.73 · Cited by 26,190
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,621
An integrated map of genetic variation from 1,092 human genomes
The 1000 Genomes Project Consortium (2012) · Nature · doi:10.1038/nature11632 · Cited by 7,711
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking
Wilkerson, M. D., & Hayes, D. N. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq170 · Cited by 5,669
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Cited by
Items 301–400 of 1,015
Han, G., Yang, G., Hao, D., Lu, Y., Thein, K., Simpson, B. S., Chen, J., Sun, R., Alhalabi, O., Wang, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25894-9 · Cited by 225
Learning from clinical trials of neoadjuvant checkpoint blockade
Versluis, J. M., Long, G. V., & Blank, C. U. (2020) · Nature Medicine · doi:10.1038/s41591-020-0829-0 · Cited by 234
Raghavan, S., Mehta, P., Xie, Y., Lei, Y. L., & Mehta, G. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0666-1 · Cited by 234
β-Catenin induces transcriptional expression of PD-L1 to promote glioblastoma immune evasion
Du, L., Lee, J.-H., Jiang, H., Wang, C., Wang, S., Zheng, Z., Shao, F., Xu, D., Xia, Y., Li, J., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20191115 · Cited by 231
Kakavand, H., Jackett, L. A., Menzies, A. M., Gide, T. N., Carlino, M. S., Saw, R. P. M., Thompson, J. F., Wilmott, J. S., Long, G. V., & Scolyer, R. A. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.89 · Cited by 223
Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology
Vanmeerbeek, I., Sprooten, J., De Ruysscher, D., Tejpar, S., Vandenberghe, P., Fucikova, J., Spisek, R., Zitvogel, L., Kroemer, G., Galluzzi, L., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2019.1703449 · Cited by 227
Mansurov, A., Ishihara, J., Hosseinchi, P., Potin, L., Marchell, T. M., Ishihara, A., Williford, J.-M., Alpar, A. T., Raczy, M. M., Gray, L. T., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-0549-2 · Cited by 235
Gajos-Michniewicz, A., & Czyz, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144852 · Cited by 222
“Gene expression profiling and exome sequencing of 266 individual melanoma metastases has revealed that about 48% of the non-inflamed melanomas exert active WNT/β-catenin pathway with elevated expression of genes under control of this signaling [171].”
BackgroundInfluentialIntratumoral Delivery of Immunotherapy—Act Locally, Think Globally
Aznar, M. A., Tinari, N., Rullán, A. J., Sánchez-Paulete, A. R., Rodriguez-Ruiz, M. E., & Melero, I. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601145 · Cited by 230
“Moreover, tumors should be injected with DC subsets capable of mediating cross-priming (115, 116), because Ags”
BackgroundTrabucco, S. E., Gowen, K., Maund, S. L., Sanford, E., Fabrizio, D. A., Hall, M. J., Yakirevich, E., Gregg, J. P., Stephens, P. J., Frampton, G. M., et al. (2019) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2019.06.011 · Cited by 222
Meyer, M. A., Baer, J. M., Knolhoff, B. L., Nywening, T. M., Panni, R. Z., Su, X., Weilbaecher, K. N., Hawkins, W. G., Ma, C., Fields, R. C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03600-6 · Cited by 217
Revisiting Immunotherapy: A Focus on Prostate Cancer
Cha, H.-R., Lee, J. H., & Ponnazhagan, S. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2948 · Cited by 223
“Some of the key directions in the field of cancer immunotherapy, in general, are geared toward identifying molecular immune mechanisms in nonresponders and developing combination therapies targeting with engineered biomolecules in the TME (110, 111), improving the potential of systemic oncolytic virotherapy (112), ada…”
BackgroundExon 3 mutations of CTNNB1 drive tumorigenesis: a review
Gao, C., Wang, Y., Broaddus, R., Sun, L., Xue, F., & Zhang, W. (2018) · Oncotarget · doi:10.18632/oncotarget.23695 · Cited by 224
“Researchers have found that β-catenin correlated to the infiltration of immune cells in the tumor microenvironment (Figure 3) [141, 142].”
BackgroundHepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies
Giraud, J., Chalopin, D., Blanc, J.-F., & Saleh, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.655697 · Cited by 221
“Previous studies in melanoma and non-small cell lung cancer (NSCLC) have attributed the response to ICIs to tumor mutational burden (86, 87), levels of neo-antigens (88) or tumorspecific antigens (89, 90), the presence of TLS [reviewed in (59)] or specific oncogenic pathways (91, 92).”
BackgroundLee, Y., Shin, J. H., Longmire, M., Wang, H., Kohrt, H. E., Chang, H. Y., & Sunwoo, J. B. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2665 · Cited by 219
“In particular, it has been recently reported that Tcell exclusion from the tumor microenvironment is controlled by theWnt pathway (57), and therefore, patients with tumors having greater CD44þ cell proportionsmay tend to be non-responders to PD-1 blockade.”
BackgroundChimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy
Srivastava, S., & Riddell, S. R. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701155 · Cited by 220
Cancer immunotherapy: it’s time to better predict patients’ response
Pilard, C., Ancion, M., Delvenne, P., Jerusalem, G., Hubert, P., & Herfs, M. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01413-x · Cited by 205
PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells
Lacher, S. B., Dörr, J., de Almeida, G. P., Hönninger, J., Bayerl, F., Hirschberger, A., Pedde, A.-M., Meiser, P., Ramsauer, L., Rudolph, T. J., et al. (2024) · Nature · doi:10.1038/s41586-024-07254-x · Cited by 207
“Priming of anticancer CD8 + T cells in tumour-draining lymph nodes (tdLNs) by type 1 conventional dendritic cells (cDC1s) that transport tumour antigens to tdLNs is thought to underlie anticancer CD8 + T cell responses 21,22 .”
BackgroundCancer‐associated fibroblasts: Key players in shaping the tumor immune microenvironment
Desbois, M., & Wang, Y. (2021) · Immunological Reviews · doi:10.1111/imr.12982 · Cited by 216
Rational Cancer Treatment Combinations: An Urgent Clinical Need
Boshuizen, J., & Peeper, D. S. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.031 · Cited by 210
Integrin αvβ6–TGFβ–SOX4 Pathway Drives Immune Evasion in Triple-Negative Breast Cancer
Bagati, A., Kumar, S., Jiang, P., Pyrdol, J., Zou, A. E., Godicelj, A., Mathewson, N. D., Cartwright, A. N. R., Cejas, P., Brown, M., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.001 · Cited by 215
“Published studies in melanoma demonstrated that a lack of CD8+ T cell infiltration can be caused by an overactive β-catenin pathway or inactivation of the PTEN tumor suppressor gene (Peng et al., 2016; Spranger et al., 2015).”
BackgroundResistance mechanisms to immune checkpoint inhibitors: updated insights
Alsaafeen, B. H., Ali, B. R., & Elkord, E. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02212-7 · Cited by 191
“…model, it was demonstrated that the activation of WNT/ β-catenin signaling promoted the resistance to anti-PD-L1 and anti-CTLA-4 monoclonal antibodies through downregulating the expression of T cell specific genes and certain chemokines, resulting in poor intratumoral T cell infiltration [83].”
Lymphatic vessels regulate immune microenvironments in human and murine melanoma
Lund, A. W., Wagner, M., Fankhauser, M., Steinskog, E. S., Broggi, M. A., Spranger, S., Gajewski, T. F., Alitalo, K., Eikesdal, H. P., Wiig, H., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci79434 · Cited by 207
“The finding that some patients lack tumorinfiltrating lymphocytes and consequently demonstrate poor response to immunotherapy (28, 29) indicates that endogenous mechanisms regulating immune induction in the tumor may be responsible for therapeutic resistance (4).”
BackgroundSelf-citationBayerl, F., Meiser, P., Donakonda, S., Hirschberger, A., Lacher, S. B., Pedde, A.-M., Hermann, C. D., Elewaut, A., Knolle, M., Ramsauer, L., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.05.011 · Cited by 203
Molecular genetics and targeted therapy of WNT-related human diseases (Review)
Katoh, M., & Katoh, M. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3071 · Cited by 207
“…(260) are β -catenin inhibitors that induce antitumor effects through repression of TCF/LEF-target genes, whereas some of these β -catenin inhibitors also show therapeutic effects in model animal experiments of non-cancerous diseases, such as pulmonary fibrosis and chronic kidney disease (261,262).”
BackgroundYang, L., Li, A., Lei, Q., & Zhang, Y. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0804-8 · Cited by 215
“[21] found that 48% of the non-T cell-inflamed tumors show evidence of WNT/β-catenin signaling pathway activation based on gene expression profiling of six defined β-catenin target genes.”
BackgroundZhang, Y., Song, J., Zhao, Z., Yang, M., Chen, M., Liu, C., Ji, J., & Zhu, D. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.10.016 · Cited by 210
Molecular and cellular paradigms of multidrug resistance in cancer
Vaidya, F. U., Sufiyan Chhipa, A., Mishra, V., Gupta, V. K., Rawat, S. G., Kumar, A., & Pathak, C. (2022) · Cancer Reports · doi:10.1002/cnr2.1291 · Cited by 197
“The increased expression of β-catenin negatively regulates CCL4, a chemokine protein that is known to attract the dendritic cells.(111) Continuous activation to interferon-gamma (IFN-γ) signaling due to consistent”
BackgroundNeoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy
Efremova, M., Finotello, F., Rieder, D., & Trajanoski, Z. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01679 · Cited by 211
“provided evidence of the existence of a neglected neoantigen repertoire that induces T-cell reactivity and may broaden neoantigen-specific T-cell reactivity and enable the targeting of neoantigens that have not been recognized by the patient’s own immune system (39).”
BackgroundAscierto, M. L., McMiller, T. L., Berger, A. E., Danilova, L., Anders, R. A., Netto, G. J., Xu, H., Pritchard, T. S., Fan, J., Cheadle, C., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0072 · Cited by 210
Desbois, M., Udyavar, A. R., Ryner, L., Kozlowski, C., Guan, Y., Dürrbaum, M., Lu, S., Fortin, J.-P., Koeppen, H., Ziai, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19408-2 · Cited by 208
Huang, T.-X., Tan, X.-Y., Huang, H.-S., Li, Y.-T., Liu, B.-L., Liu, K.-S., Chen, X., Chen, Z., Guan, X.-Y., Zou, C., et al. (2022) · Gut · doi:10.1136/gutjnl-2020-322924 · Cited by 200
Corrales, L., & Gajewski, T. F. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1362 · Cited by 197
“Type I IFNs and the STING pathway in cancer Spontaneous T cell responses against tumors in vivo have been observed, both in human cancer patients and in murine models (18).”
BackgroundSelf-citationZhou, J., Liu, M., Sun, H., Feng, Y., Xu, L., Chan, A. W. H., Tong, J. H., Wong, J., Chong, C. C. N., Lai, P. B. S., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-314032 · Cited by 201
Momin, N., Mehta, N. K., Bennett, N. R., Ma, L., Palmeri, J. R., Chinn, M. M., Lutz, E. A., Kang, B., Irvine, D. J., Spranger, S., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw2614 · Cited by 204
“This model has modest T cell infiltration, but growth is only slightly slowed by dual checkpoint blockade of PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (42).”
Self-citationYu, J. W., Bhattacharya, S., Yanamandra, N., Kilian, D., Shi, H., Yadavilli, S., Katlinskaya, Y., Kaczynski, H., Conner, M., Benson, W., et al. (2018) · PLOS ONE · doi:10.1371/journal.pone.0206223 · Cited by 206
Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors
Siemers, N. O., Holloway, J. L., Chang, H., Chasalow, S. D., Ross-MacDonald, P. B., Voliva, C. F., & Szustakowski, J. D. (2017) · PLOS ONE · doi:10.1371/journal.pone.0179726 · Cited by 203
The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity
Baumgartner, C. K., Ebrahimi-Nik, H., Iracheta-Vellve, A., Hamel, K. M., Olander, K. E., Davis, T. G. R., McGuire, K. A., Halvorsen, G. T., Avila, O. I., Patel, C. H., et al. (2023) · Nature · doi:10.1038/s41586-023-06575-7 · Cited by 186
“Ranked lists of differential genes were created using signed P values calculated by the logistic regression model and passed to GSEAPreranked to search for enriched gene sets by treatment 18,55,60 .”
MethodGenomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based Subtypes
Zhang, L., MacIsaac, K. D., Zhou, T., Huang, P.-Y., Xin, C., Dobson, J. R., Yu, K., Chiang, D. Y., Fan, Y., Pelletier, M., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0134 · Cited by 201
“A role for TGFb in immunomodulation has been well described (40), and recent reports in melanoma have proposed a role for WNT signaling in regulating antitumor immune responses (41).”
BackgroundLi, F., Huang, Q., Luster, T. A., Hu, H., Zhang, H., Ng, W.-L., Khodadadi-Jamayran, A., Wang, W., Chen, T., Deng, J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0780 · Cited by 203
“1B), consistent with findings that β-catenin or MAPK3 inhibition promotes sensitivity to immune checkpoint blockade (26, 27).”
BackgroundStudy and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker
Wang, Z., & Wu, X. (2020) · Cancer Medicine · doi:10.1002/cam4.3410 · Cited by 195
Zhang, C., Li, J., Cheng, Y., Meng, F., Song, J.-W., Fan, X., Fan, H., Li, J., Fu, Y.-L., Zhou, M.-J., et al. (2023) · Gut · doi:10.1136/gutjnl-2021-325915 · Cited by 193
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
Arora, S., Velichinskii, R., Lesh, R. W., Ali, U., Kubiak, M., Bansal, P., Borghaei, H., Edelman, M. J., & Boumber, Y. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01051-z · Cited by 196
Barriers to Radiation-Induced In Situ Tumor Vaccination
Wennerberg, E., Lhuillier, C., Vanpouille-Box, C., Pilones, K. A., García-Martínez, E., Rudqvist, N.-P., Formenti, S. C., & Demaria, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00229 · Cited by 194
“Myeloid cells in the tumor microenvironment (TME) are polarized toward an immunosuppressive phenotype, and DCs acquire a tolerogenic function or are excluded altogether from the tumor (23).”
BackgroundPark, Y.-J., Kuen, D.-S., & Chung, Y. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0130-1 · Cited by 194
Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
Cancel, J.-C., Crozat, K., Dalod, M., & Mattiuz, R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00009 · Cited by 194
“Second, reciprocally, cDC1 ability to produce high levels of CXCL9/10 may promote local recruitment of effector and memory CTLs expressing CXCR3 (43, 57, 64).”
BackgroundInfluentialAnagnostou, V., Niknafs, N., Marrone, K., Bruhm, D. C., White, J. R., Naidoo, J., Hummelink, K., Monkhorst, K., Lalezari, F., Lanis, M., et al. (2020) · Nature Cancer · doi:10.1038/s43018-019-0008-8 · Cited by 200
Reprogramming the immunological microenvironment through radiation and targeting Axl
Aguilera, T. A., Rafat, M., Castellini, L., Shehade, H., Kariolis, M. S., Hui, A. B.-Y., Stehr, H., von Eyben, R., Jiang, D., Ellies, L. G., et al. (2016) · Nature Communications · doi:10.1038/ncomms13898 · Cited by 194
Melanoma: What do all the mutations mean?
Davis, E. J., Johnson, D. B., Sosman, J. A., & Chandra, S. (2018) · Cancer · doi:10.1002/cncr.31345 · Cited by 180
“implications, CTNNB1 signaling also has been implicated in immune cell exclusion.(93) Finally, low-frequency mutations in ARID2, PPP6C, MAP2K1, IDH1, RB1, and many others have been described.”
BackgroundTargeting Wnt/β-Catenin Signaling for Cancer Immunotherapy
Wang, B., Tian, T., Kalland, K.-H., Ke, X., & Qu, Y. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.03.008 · Cited by 192
Zhong, W., Myers, J. S., Wang, F., Wang, K., Lucas, J., Rosfjord, E., Lucas, J., Hooper, A. T., Yang, S., Lemon, L. A., et al. (2020) · BMC Genomics · doi:10.1186/s12864-019-6344-3 · Cited by 184
“Recent studies [25, 26] implicated activation of the β-catenin oncogenic pathway as inducing resistance to anti-tumor immunity in melanoma.”
BackgroundEpigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy
Li, J., Wang, W., Zhang, Y., Cieślik, M., Guo, J., Tan, M., Green, M. D., Wang, W., Lin, H., Li, W., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134402 · Cited by 191
Metabolism‐associated molecular classification of hepatocellular carcinoma
Yang, C., Huang, X., Liu, Z., Qin, W., & Wang, C. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12639 · Cited by 189
“Previous studies have revealed that tumor-intrinsic active b-catenin signaling may lead to T-cell exclusion, thus resistance toward anti-PD-L1 and anti-CTLA4 (Spranger et al., 2015), which is consistent with the insensitivity toward immune blockade in C1 patients of our study.”
ResultSarode, P., Zheng, X., Giotopoulou, G. A., Weigert, A., Kuenne, C., Günther, S., Friedrich, A., Gattenlöhner, S., Stiewe, T., Brüne, B., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz6105 · Cited by 191
Dendritic Cell Metabolism and Function in Tumors
Giovanelli, P., Sandoval, T. A., & Cubillos-Ruiz, J. R. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.06.004 · Cited by 187
Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation
Kandalaft, L. E., Dangaj Laniti, D., & Coukos, G. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00503-z · Cited by 180
Defining and Understanding Adaptive Resistance in Cancer Immunotherapy
Kim, T. K., Herbst, R. S., & Chen, L. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.05.001 · Cited by 192
Dendritic cell maturation in cancer
Moon, C. Y., Belabed, M., Park, M. D., Mattiuz, R., Puleston, D., & Merad, M. (2025) · Nature Reviews Cancer · doi:10.1038/s41568-024-00787-3 · Cited by 170
“In some cancer types, such as β-catenin + tumours, an absence of DCs at the tumour site is thought to drive resistance to ICB, which is partly driven by decreased recruitment of effector T cells by DCs 19,282 .”
WNT signaling and cancer stemness
Katoh, M., & Katoh, M. (2022) · Essays in Biochemistry · doi:10.1042/ebc20220016 · Cited by 179
Gordon-Alonso, M., Hirsch, T., Wildmann, C., & van der Bruggen, P. (2017) · Nature Communications · doi:10.1038/s41467-017-00925-6 · Cited by 186
Immune cell subset differentiation and tissue inflammation
Fang, P., Li, X., Dai, J., Cole, L., Camacho, J. A., Zhang, Y., Ji, Y., Wang, J., Yang, X.-F., & Wang, H. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0637-x · Cited by 183
Rodon, J., Argilés, G., Connolly, R. M., Vaishampayan, U., de Jonge, M., Garralda, E., Giannakis, M., Smith, D. C., Dobson, J. R., McLaughlin, M. E., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01389-8 · Cited by 174
“The chemokine signature was based on the expression of the following genes: CCL2, CCL3, CCL4, CCL5, CXCL9, and CXCL10(20); the activated dendritic cell signature was based on the expression of BATF3, CCR5, CXCL1, ITGAE, CCL3, IRF8, and CCL4.(13)”
BackgroundMethodInfluentialLow neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer
Westcott, P. M. K., Sacks, N. J., Schenkel, J. M., Ely, Z. A., Smith, O., Hauck, H., Jaeger, A. M., Zhang, D., Backlund, C. M., Beytagh, M. C., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00247-z · Cited by 175
Hendrickx, W., Simeone, I., Anjum, S., Mokrab, Y., Bertucci, F., Finetti, P., Curigliano, G., Seliger, B., Cerulo, L., Tomei, S., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1253654 · Cited by 185
Liu, X.-D., Kong, W., Peterson, C. B., McGrail, D. J., Hoang, A., Zhang, X., Lam, T., Pilie, P. G., Zhu, H., Beckermann, K. E., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15959-6 · Cited by 177
Zheng, S., Wang, W., Shen, L., Yao, Y., Xia, W., & Ni, C. (2024) · Experimental Hematology & Oncology · doi:10.1186/s40164-024-00543-1 · Cited by 163
Lack of immunoediting in murine pancreatic cancer reversed with neoantigen
Evans, R. A., Diamond, M. S., Rech, A. J., Chao, T., Richardson, M. W., Lin, J. H., Bajor, D. L., Byrne, K. T., Stanger, B. Z., Riley, J. L., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.88328 · Cited by 180
“regulate progression-free survival and T cell infiltration in other mouse models (22, 25, 26).”
BackgroundDiverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms
Bezzi, M., Seitzer, N., Ishikawa, T., Reschke, M., Chen, M., Wang, G., Mitchell, C., Ng, C., Katon, J., Lunardi, A., et al. (2018) · Nature Medicine · doi:10.1038/nm.4463 · Cited by 172
Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer
Terranova-Barberio, M., Pawlowska, N., Dhawan, M., Moasser, M., Chien, A. J., Melisko, M. E., Rugo, H., Rahimi, R., Deal, T., Daud, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17414-y · Cited by 177
Genomic Approaches to Understanding Response and Resistance to Immunotherapy
Braun, D. A., Burke, K. P., & Van Allen, E. M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0066 · Cited by 179
“In amousemodel lackingBRAF andPTEN, they then demonstrated that b-catenin signaling was necessary for effective dendritic cell recruitment as well as initial T-cell priming and infiltration (51).”
BackgroundToward Precision Radiotherapy for Use with Immune Checkpoint Blockers
Vanpouille-Box, C., Formenti, S. C., & Demaria, S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0037 · Cited by 171
Inhibitors of the PD-1 Pathway in Tumor Therapy
LaFleur, M. W., Muroyama, Y., Drake, C. G., & Sharpe, A. H. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701044 · Cited by 175
“Tumors in which this pathway was active were relatively noninflamed, that is, cold, and hence far less likely to respond to PD-1/PD-L1 blockade (105).”
Induction of Tolerance and Immunity by Dendritic Cells: Mechanisms and Clinical Applications
Fucikova, J., Palova-Jelinkova, L., Bartunkova, J., & Spisek, R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02393 · Cited by 173
Ascierto, P. A., Agarwala, S., Botti, G., Cesano, A., Ciliberto, G., Davies, M. A., Demaria, S., Dummer, R., Eggermont, A. M., Ferrone, S., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1070-y · Cited by 173
Self-citationHennequart, M., Pilotte, L., Cane, S., Hoffmann, D., Stroobant, V., Plaen, E. D., & Eynde, B. J. V. D. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0400 · Cited by 171
Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis
Lin, J. H., Huffman, A. P., Wattenberg, M. M., Walter, D. M., Carpenter, E. L., Feldser, D. M., Beatty, G. L., Furth, E. E., & Vonderheide, R. H. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20190673 · Cited by 178
Widemann, B. C., & Italiano, A. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3467 · Cited by 168
“Of note, activation of the b-catenin signaling has been found to be involved in preventing antitumor immunity in melanoma.(17) However, correlation between these different pathways of interest and immunity involvement in tumor has not been assessed in UPS.”
BackgroundWhite paper on microbial anti-cancer therapy and prevention
Forbes, N. S., Coffin, R. S., Deng, L., Evgin, L., Fiering, S., Giacalone, M., Gravekamp, C., Gulley, J. L., Gunn, H., Hoffman, R. M., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0381-3 · Cited by 168
“The mechanisms of acquired resistance to ICB include, but are not limited to: (1) loss of tumor-suppressor gene, such as PTEN [51, 53] or overexpression of β-catenin [52], (2) up-regulation of inhibitory molecules such as PD-L1 and VISTA [50], (3) loss of neoantigens in the evolved tumors [49], (4) epigenetic silencin…”
BackgroundUnderstanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
Shergold, A. L., Millar, R., & Nibbs, R. J. B. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104258 · Cited by 174
Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes
Kim, S. I., Cassella, C. R., & Byrne, K. T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.629722 · Cited by 168
Germline genetic contribution to the immune landscape of cancer
Sayaman, R. W., Saad, M., Thorsson, V., Hu, D., Hendrickx, W., Roelands, J., Porta-Pardo, E., Mokrab, Y., Farshidfar, F., Kirchhoff, T., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.01.011 · Cited by 179
Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses
Blagih, J., Zani, F., Chakravarty, P., Hennequart, M., Pilley, S., Hobor, S., Hock, A. K., Walton, J. B., Morton, J. P., Gronroos, E., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2019.12.028 · Cited by 173
Yang, W., Feng, Y., Zhou, J., Cheung, O. K.-W., Cao, J., Wang, J., Tang, W., Tu, Y., Xu, L., Wu, F., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz6804 · Cited by 172
“Our previous study has shown that HDAC8 cooperates with the enhancer of zeste homolog 2 repressor to epigenetically activate Wnt/-catenin signaling (51), which may result in subsequent defective recruitment of dendritic cells through reduced CCL4 and CCL5 expression (52), impaired T cell activity, and unresponsivenes…”
MethodHilmi, M., Neuzillet, C., Calderaro, J., Lafdil, F., Pawlotsky, J.-M., & Rousseau, B. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0824-5 · Cited by 172
Dendritic cells in the tumor microenvironment: prognostic and theranostic impact
Verneau, J., Sautés-Fridman, C., & Sun, C.-M. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101410 · Cited by 165
Horton, B. L., Williams, J. B., Cabanov, A., Spranger, S., & Gajewski, T. F. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0249 · Cited by 168
Self-citationTumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers
Mushtaq, M. U., Papadas, A., Pagenkopf, A., Flietner, E., Morrow, Z., Chaudhary, S. G., & Asimakopoulos, F. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0376-0 · Cited by 165
Tumor cell–intrinsic EPHA2 suppresses antitumor immunity by regulating PTGS2 (COX-2)
Markosyan, N., Li, J., Sun, Y. H., Richman, L. P., Lin, J. H., Yan, F., Quinones, L., Sela, Y., Yamazoe, T., Gordon, N., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127755 · Cited by 170
“Instead, recent work has pointed to the critical importance of tumor cell–intrinsic factors — secreted factors, signaling pathways, and epigenetic status — in shaping the tumor immune microenvironment in both PDA (8, 11, 12, 15, 16) and other tumor types (17–22).”
T lymphocyte membrane-decorated epigenetic nanoinducer of interferons for cancer immunotherapy
Zhai, Y., Wang, J., Lang, T., Kong, Y., Rong, R., Cai, Y., Ran, W., Xiong, F., Zheng, C., Wang, Y., et al. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00972-7 · Cited by 170
IFNγ-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin
Lane, R. S., Femel, J., Breazeale, A. P., Loo, C. P., Thibault, G., Kaempf, A., Mori, M., Tsujikawa, T., Chang, Y. H., & Lund, A. W. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20180654 · Cited by 165
“Scores were calculated as the first principal component of each gene set: LS, VEG FC, LYVE1, and PDPN; T cell inflammation score: CD8A, CCL2, CCL3, CCL4, CXCL9, CXCL10, ICOS, GZMK, IRF1, HLA-DMA, HLA-DMB, HLA-DOA, and HLADOB (Spranger et al., 2015); type II IFN score: IFNΓ, STAT1, CCR5, CXCL9, PRF1, HLA-DRA, CXCL10, C…”
MethodChoucair, K., Morand, S., Stanbery, L., Edelman, G., Dworkin, L., & Nemunaitis, J. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-0174-y · Cited by 164
“Similarly, alterations in β-catenin/WNT signalling causes decrease in CCL4 production and a subsequent diminished infiltration of dendritic cells (DCs), poor APC functions, and impaired immune response [57].”
BackgroundDual Role of WISP1 in maintaining glioma stem cells and tumor-supportive macrophages in glioblastoma
Tao, W., Chu, C., Zhou, W., Huang, Z., Zhai, K., Fang, X., Huang, Q., Zhang, A., Wang, X., Yu, X., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16827-z · Cited by 162
Microenvironmental IL-6 inhibits anti-cancer immune responses generated by cytotoxic chemotherapy
Bent, E. H., Millán-Barea, L. R., Zhuang, I., Goulet, D. R., Fröse, J., & Hemann, M. T. (2021) · Nature Communications · doi:10.1038/s41467-021-26407-4 · Cited by 159
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis
Passiglia, F., Bronte, G., Bazan, V., Natoli, C., Rizzo, S., Galvano, A., Listì, A., Cicero, G., Rolfo, C., Santini, D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7582 · Cited by 165
“Recent evidences suggested two different pathways modulating the PD-L1 expression on the tumor cell surface: the “inflammation-driven”, INF-gamma-mediated, PD-L1 expression, which is localized at sites of inflammation and is usually associated with a baseline tumor T-cell infiltration; and the “oncogene-driven”, PD-L1…”
BackgroundThe immune landscape and response to immune checkpoint blockade therapy in lymphoma
Kline, J., Godfrey, J., & Ansell, S. M. (2020) · Blood · doi:10.1182/blood.2019000847 · Cited by 167
Derks, S., de Klerk, L. K., Xu, X., Fleitas, T., Liu, K. X., Liu, Y., Dietlein, F., Margolis, C., Chiaravalli, A. M., Da Silva, A. C., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.04.011 · Cited by 163
Newell, F., Pires da Silva, I., Johansson, P. A., Menzies, A. M., Wilmott, J. S., Addala, V., Carlino, M. S., Rizos, H., Nones, K., Edwards, J. J., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2021.11.012 · Cited by 164
Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
Conway, J. R., Kofman, E., Mo, S. S., Elmarakeby, H., & Van Allen, E. (2018) · Genome Medicine · doi:10.1186/s13073-018-0605-7 · Cited by 165
Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance
Lin, H., Kryczek, I., Li, S., Green, M. D., Ali, A., Hamasha, R., Wei, S., Vatan, L., Szeliga, W., Grove, S., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.023 · Cited by 159
“…Shin et al., 2017; Zaretsky et al., 2016), dysfunctional T-cell trafficking and cytotoxic T cell activity (Peng et al., 2015; Sheng et al., 2018; Spranger et al., 2015), abnormal metabolic networks (Bian et al., 2020; Buck et al., 2016; Karmaus et al., 2019; Li et al., 2018; Maj et al., 2017),…”
BackgroundSynergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer
Herter-Sprie, G. S., Koyama, S., Korideck, H., Hai, J., Deng, J., Li, Y. Y., Buczkowski, K. A., Grant, A. K., Ullas, S., Rhee, K., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.87415 · Cited by 161
Metadata
- Authors
- Spranger, S., Bao, R., & Gajewski, T. F.
- Affiliations
- University of Chicago (US)
- Corresponding author
- Gajewski, Thomas F.
- Venue
- Nature
- Published
- 2015-05-11
- Volume
- 523
- Issue
- 7559
- Pages
- 231-235
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1498931318
- Cited by
- 2,830
- References
- 45
- Citations by year
- 2026: 240 · 2025: 234 · 2024: 222 · 2023: 270 · 2022: 319 · 2021: 367 · 2020: 337 · 2019: 246 · 2018: 198 · 2017: 212 · 2016: 151 · 2015: 31
- FWCI
- 86.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- melanoma, β-catenin signaling, Wnt signaling, cancer immunotherapy resistance, PD-L1 blockade, CTLA-4 blockade, T-cell exclusion, tumor microenvironment, CD8+ T cell infiltration, tumor immune evasion, oncogenic signaling, immune checkpoint blockade
- MeSH terms
- Animals, Humans, Immunotherapy, Melanoma, T-Lymphocytes, Signal Transduction, Gene Expression Regulation, Neoplastic, Gene Expression Profiling, Wnt Proteins, beta Catenin, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.